GW Pharmaceuticals, which makes drugs derived from the cannabis plant, is scaling up its manufacturing capacity ahead of an expected approval of a new treatment for children with life-threatening epilepsy.

The U.S. Food and Drug Administration (FDA) has granted GW Pharmaceuticals Plc's experimental cannabis-derived epilepsy drug "orphan" status for a third group of patients affected by a rare form of the disease.

Marijuana extract reduces seizures in patients with Lennox-Gastaut Syndrome in clinical trial.

An oil derived from the marijuana plant sharply reduces violent seizures in young people suffering from a rare, severe form of epilepsy, according to a study published Wednesday that gives more hope to parents who have been clamoring for access to the medication.

An experimental drug derived from marijuana has succeeded in reducing epileptic seizures in its first major clinical trial, the product’s developer announced Monday, a finding that could lend credence to the medical marijuana movement.